N-Acetylcysteine for thrombotic thrombocytopenic purpura: Is a von Willebrand factor-inhibitory dose feasible in vivo?

Transfusion

Volumn 54, Issue 9, 2014, Pages 2362-2363

  Shortt, Jake ^a   Opat, Stephen S ^a   Wood, Erica M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE;

DISEASE SEVERITY; FEASIBILITY STUDY; HEMOLYSIS; HUMAN; IN VIVO STUDY; LETTER; PLASMAPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; FEMALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ACETYLCYSTEINE; FEMALE; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84908143754     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12787     Document Type: Letter

References (4)

1. Li GW, Rambally S, Kamboj J, et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion 2014;54:1221-4.
2. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013;368:90-2.
3. Chen J, Reheman A, Gushiken FC, et al. N-acetylycysteine reduces the size and activity of von-Willebrand factor in human plasma and mice. J Clin Invest 2011;121:593-603.
4. Prescott LF, Donovan JW, Jarvie DR, et al. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 1989;37:501-6.